公开(公告)号：US20130324370A1

公开(公告)日：2013-12-05

申请号：US13654396

申请日：2012-10-17

Applicant: Daniel Connolly Harrigan

Inventor： Daniel Connolly Harrigan

IPC: A63B69/34

CPC classification number: A63B69/34 ,  A63B69/004 ,  A63B69/32 ,  A63B71/0622 ,  A63B2071/0625 ,  A63B2220/53 ,  A63B2220/801 ,  A63B2220/833

Abstract: A midi tongue drum wing chun dummy adapted to play sounds and emit lights when the dummy is impacted by a practitioner. The dummy enables practitioners to practice dangerous techniques without the aid of human person and also increase their familiarity and accuracy with striking pressure points in the body.

Abstract translation: 一个i舌鼓un un un dummy dummy dummy when when when when when when when when。。。。。。。。。。。。。。。 虚拟人员可以让实践者在没有人类帮助的情况下练习危险的技术，并通过身体的压力点增加他们的熟练程度和准确性。

公开(公告)号：US20070079392A1

公开(公告)日：2007-04-05

申请号：US11603625

申请日：2006-11-22

Applicant: Chen Liaw ,  Dominic Behan ,  Derek Chalmers ,  Michael Lerner ,  Huong Dang ,  Bryan Choi ,  James Leonard ,  Yaron Hakak ,  Kevin Lowitz ,  David Unett ,  Ruoping Chen ,  Jeremy Richman ,  Daniel Connolly

Inventor： Chen Liaw ,  Dominic Behan ,  Derek Chalmers ,  Michael Lerner ,  Huong Dang ,  Bryan Choi ,  James Leonard ,  Yaron Hakak ,  Kevin Lowitz ,  David Unett ,  Ruoping Chen ,  Jeremy Richman ,  Daniel Connolly

IPC: A01K67/027 ,  G01N33/53 ,  C12P21/06 ,  C07D403/02 ,  C07K14/705

CPC classification number: C07D403/02 ,  A01K2217/00 ,  A01K2227/105 ,  A01K2267/03 ,  A61K31/4439 ,  C07K14/705 ,  G01N33/566 ,  G01N2333/726 ,  G01N2500/00

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

Abstract translation: 本发明涉及鉴定候选化合物是G蛋白偶联受体（GPCR）的调节剂的方法。 在优选的实施方案中，GPCR是人。 在其它优选实施方案中，GPCR与Gi偶联并降低细胞内cAMP的水平。 在其它优选实施方案中，GPCR由脂肪细胞内源性表达。 在进一步优选的实施方案中，GPCR抑制细胞内脂肪分解。 在其它进一步优选的实施方案中，GPCR是烟酸受体。 本发明还涉及使用所述GPCR的调节剂的方法。 优选的调节剂是激动剂。 本发明的激动剂可用作预防或治疗代谢相关疾病，包括血脂异常，动脉粥样硬化，冠心病，中风，胰岛素抵抗和2型糖尿病的治疗剂。

公开(公告)号：US20070072861A1

公开(公告)日：2007-03-29

申请号：US11387554

申请日：2006-03-23

Applicant: Barbara Roniker ,  Richard LaChapelle ,  Daniel Connolly ,  Karen Seibert ,  Philip Needleman

Inventor： Barbara Roniker ,  Richard LaChapelle ,  Daniel Connolly ,  Karen Seibert ,  Philip Needleman

IPC: A61K31/50 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/42 ,  A61K31/401 ,  A61K31/366 ,  A61K31/365 ,  A61K31/22

CPC classification number: A61K45/06 ,  A61K31/22 ,  A61K31/365 ,  A61K31/366 ,  A61K31/401 ,  A61K31/415 ,  A61K31/42 ,  A61K31/421 ,  A61K31/4439 ,  A61K31/50 ,  A61K2300/00

Abstract: This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing cardiovascular disorders.

Abstract translation: 本发明涉及环氧合酶-2抑制剂或其衍生物在预防心血管疾病中的应用。

公开(公告)号：US20050238579A1

公开(公告)日：2005-10-27

申请号：US10523100

申请日：2003-07-25

Applicant: John Adams ,  Daniel Connolly

Inventor： John Adams ,  Daniel Connolly

IPC: A01K67/027 ,  A61K38/17 ,  A61K45/00 ,  A61K51/00 ,  A61K51/08 ,  A61P9/04 ,  A61P9/10 ,  A61P43/00 ,  C07K14/705 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N9/14 ,  C12N15/09 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/53 ,  G01N33/567 ,  G01N33/74

CPC classification number: G01N33/74 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2267/03 ,  C07K14/705 ,  G01N2333/726 ,  G01N2500/04

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia/reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

Abstract translation: 本发明涉及鉴定候选化合物是否为孤儿G蛋白偶联受体（GPCR）的调节剂的方法。 优选GPCR是人。 在一些实施方案中，GPCR由心肌细胞内源性表达。 在一些实施方案中，GPCR与Gi偶联并降低细胞内cAMP的水平。 在一些实施方案中，GPCR的过表达促进心肌细胞的存活。 在一些实施方案中，GPCR的过表达从心肌缺血/再氧化诱导的细胞凋亡中拯救心肌细胞。 在一些实施方案中，GPCR在具有充血性心力衰竭的个体中下调。 预期本发明的激动剂可用作治疗缺血性心脏病，包括心肌梗死，心肌梗死后重建和充血性心力衰竭的治疗剂。

公开(公告)号：US20050004178A1

公开(公告)日：2005-01-06

申请号：US10897815

申请日：2004-07-23

Applicant: David Unett ,  Ruoping Chen ,  Jeremy Richman ,  Daniel Connolly ,  Chen Liaw ,  Dominic Behan ,  Derek Chalmers ,  Michael Lerner ,  Huong Dang ,  Bryan Choi ,  James Leonard ,  Yaron Hakak ,  Kevin Lowitz

Inventor： David Unett ,  Ruoping Chen ,  Jeremy Richman ,  Daniel Connolly ,  Chen Liaw ,  Dominic Behan ,  Derek Chalmers ,  Michael Lerner ,  Huong Dang ,  Bryan Choi ,  James Leonard ,  Yaron Hakak ,  Kevin Lowitz

IPC: A61K31/4439 ,  G01N33/566 ,  G01N33/53

CPC classification number: C07D403/02 ,  A01K2217/00 ,  A01K2227/105 ,  A01K2267/03 ,  A61K31/4439 ,  C07K14/705 ,  G01N33/566 ,  G01N2333/726 ,  G01N2500/00

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

公开(公告)号：US20110177612A1

公开(公告)日：2011-07-21

申请号：US12881014

申请日：2010-09-13

Applicant: David J. Unett ,  Ruoping Chen ,  Jeremy G. Richman ,  Daniel Connolly ,  Huong T. Dang ,  Bryan Choi ,  James Leonard ,  Yaron Hakak ,  Chen Liaw ,  Dominic Behan ,  Derek Chalmers ,  Michael Lerner ,  Kevin P. Lowitz

Inventor： David J. Unett ,  Ruoping Chen ,  Jeremy G. Richman ,  Daniel Connolly ,  Huong T. Dang ,  Bryan Choi ,  James Leonard ,  Yaron Hakak ,  Chen Liaw ,  Dominic Behan ,  Derek Chalmers ,  Michael Lerner ,  Kevin P. Lowitz

IPC: G01N33/68

CPC classification number: C07D403/02 ,  A01K2217/00 ,  A01K2227/105 ,  A01K2267/03 ,  A61K31/4439 ,  C07K14/705 ,  G01N33/566 ,  G01N2333/726 ,  G01N2500/00

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In preferred embodiments, the GPCR is human. In other preferred embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In other preferred embodiments, the GPCR is expressed endogenously by adipocytes. In further preferred embodiments, the GPCR inhibits intracellular lipolysis. In other further preferred embodiments, the GPCR is a nicotinic acid receptor. The present invention also relates to methods of using a modulator of said GPCR. Preferred modulator is agonist. Agonists of the invention are useful as therapeutic agents for the prevention or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, stroke, insulin resistance, and type 2 diabetes.

Abstract translation: 本发明涉及鉴定候选化合物是G蛋白偶联受体（GPCR）的调节剂的方法。 在优选的实施方案中，GPCR是人。 在其它优选实施方案中，GPCR与Gi偶联并降低细胞内cAMP的水平。 在其它优选实施方案中，GPCR由脂肪细胞内源性表达。 在进一步优选的实施方案中，GPCR抑制细胞内脂肪分解。 在其它进一步优选的实施方案中，GPCR是烟酸受体。 本发明还涉及使用所述GPCR的调节剂的方法。 优选的调节剂是激动剂。 本发明的激动剂可用作预防或治疗代谢相关疾病，包括血脂异常，动脉粥样硬化，冠心病，中风，胰岛素抵抗和2型糖尿病的治疗剂。

公开(公告)号：US20070231792A1

公开(公告)日：2007-10-04

申请号：US10561132

申请日：2004-06-17

Applicant: John Adams ,  Daniel Connolly

Inventor： John Adams ,  Daniel Connolly

IPC: C12Q1/68 ,  G01N33/53 ,  A61K38/55 ,  A01K67/027

CPC classification number: G01N33/74 ,  A01K67/027 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/705 ,  C07K14/723 ,  C07K2319/00 ,  C12N2799/022 ,  G01N33/6893 ,  G01N33/76 ,  G01N2333/726 ,  G01N2800/32 ,  G01N2800/325

Abstract: The present invention relates to methods of identifying whether a candidate compound is a modulator of a G protein-coupled receptor (GPCR). In some embodiments, the GPCR is mammalian, preferably human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gq. In some embodiments, the GPCR increases the intracellular level of inositol 1,4,5-triphosphate (IP3). In some embodiments, a modulator of the GPCR is a modulator of cardiomyocyte hypertrophy. The present invention further relates to methods of using a modulator of the GPCR. Preferred modulators are inverse agonists and antagonists. Inverse agonists and antagonists of the invention are useful as therapeutic agents for the prevention or treatment of heart disease, including hypertrophic cardiomyopathy and congestive heart failure, in particular hypertrophic cardiomyopathy resulting from post-myocardial infarction remodeling, cardiac valve disease, sustained cardiac afterload, myocarditis, and familial hypertrophic cardiomyopathy.

Abstract translation: 本发明涉及鉴定候选化合物是G蛋白偶联受体（GPCR）的调节剂的方法。 在一些实施方案中，GPCR是哺乳动物，优选人。 在一些实施方案中，GPCR由心肌细胞内源性表达。 在一些实施例中，GPCR耦合到Gq。 在一些实施方案中，GPCR增加1,4,5-三磷酸肌醇（IP3）的细胞内水平。 在一些实施方案中，GPCR的调节剂是心肌细胞肥大的调节剂。 本发明还涉及使用GPCR调制器的方法。 优选的调节剂是反向激动剂和拮抗剂。 本发明的反向激动剂和拮抗剂可用作预防或治疗心脏病，包括肥厚性心肌病和充血性心力衰竭的治疗剂，特别是由心肌梗死后重建，心脏瓣膜疾病，持续的心脏后负荷，心肌炎引起的肥大性心肌病 ，和家族性肥厚型心肌病。

公开(公告)号：US20070203246A1

公开(公告)日：2007-08-30

申请号：US11742764

申请日：2007-05-01

Applicant: Bradley Keller ,  James Sikorski ,  Kevin Glenn ,  Daniel Connolly ,  Mark Smith

Inventor： Bradley Keller ,  James Sikorski ,  Kevin Glenn ,  Daniel Connolly ,  Mark Smith

IPC: A61K31/135

CPC classification number: A61K31/585 ,  A61K31/135 ,  A61K31/22 ,  A61K31/36 ,  A61K31/405 ,  A61K31/55 ,  A61K31/575 ,  A61K31/785 ,  A61K45/06 ,  Y10S514/824 ,  A61K2300/00

Abstract: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.

Abstract translation: 本发明提供用于预防或治疗包括高胆固醇血症，动脉粥样硬化或高脂血症的心血管疾病的心血管治疗化合物的组合。 所公开的组合包括与胆固醇酯转移蛋白（CETP）抑制剂组合的HMG CoA还原酶抑制剂。

公开(公告)号：US20050212502A1

公开(公告)日：2005-09-29

申请号：US10810864

申请日：2004-03-29

Applicant: Charles Casey ,  Daniel Connolly ,  Brant Johnson

Inventor： Charles Casey ,  Daniel Connolly ,  Brant Johnson

IPC: G05F1/40 ,  H02M3/00 ,  H02M3/156 ,  H02M3/28 ,  H02M3/335

CPC classification number: H02M3/156

Abstract: In one embodiment, a power supply controller of a power supply system uses an algorithm to reduce the number of drive pulses to the output transistors under light load conditions. The algorithm groups the drive pulses to the output transistors into sets and removes some of the drive pulses for each set drive pulses issued by the controller. Each successive set removes additional drive pulses.

Abstract translation: 在一个实施例中，供电系统的电源控制器使用一种算法来在轻负载条件下减少输出晶体管的驱动脉冲数。 该算法将输出晶体管的驱动脉冲组合成组，并且去除由控制器发出的每组设置的驱动脉冲的一些驱动脉冲。 每个连续的设置去除额外的驱动脉冲。

公开(公告)号：US20150065312A1

公开(公告)日：2015-03-05

申请号：US14535488

申请日：2014-11-07

Applicant: Daniel Connolly Harrigan

Inventor： Daniel Connolly Harrigan

IPC: A63B69/00 ,  A63B69/34

CPC classification number: A63B69/004 ,  A63B69/32 ,  A63B69/34 ,  A63B71/0622 ,  A63B2071/0625 ,  A63B2220/53 ,  A63B2220/801 ,  A63B2220/833

Abstract: A martial arts sensitivity and speed training device and method is provided. The training device may be a midi tongue drum wing chun dummy adapted to play sounds when the dummy is impacted by a practitioner. The dummy enables practitioners to practice dangerous techniques without the aid of human person and also increase their familiarity, sensitivity, speed and accuracy with striking acupuncture and related pressure points on the body of a human person.

Abstract translation: 提供武术灵敏度和速度训练装置及方法。 训练装置可以是适于在虚拟人受到执业者的影响时播放声音的mid舌鼓翼弹簧。 虚拟人员可以在没有人的帮助的情况下使练习者练习危险的技术，并且通过在人体上引发针灸和相关的压力点，增加他们的熟悉程度，敏感度，速度和准确性。